Cancer Pharmacology Research

The Cancer research group has successfully established itself at ANZAC, following the appointment of Prof Stephen Clarke to the Chair of Medicine. Since joining two years ago, the team has significantly increased cancer research activities on the Concord campus in multiple areas. These include clinical trials of new cancer treatments, nutritional and psycho-oncology research and the establishment of a molecular-based cancer pharmacology laboratory. In addition, a strong collaboration with the Australian Proteome Analysis Facility at Macquarie University has enabled our scientists to search for new biomarkers for Colorectal cancer. This has led to a successful Cancer Institute NSW translational program grant for $3.75 million over 5 years. The appointment of Prof Andrew McLachlan (Faculty of Pharmacy, Uni of Sydney) to the Chair of Geriatric Pharmacy on the Concord campus strengthens the pharmacokinetic and analytical expertise required for clinical drug studies in cancer patients.

Our Research Program includes:

Colorectal Cancer Biomarker Studies and Clinical Trials
details here

Cancer Pharmacology and Cachexia
- Drug clearance and cancer treatments
details here
- Do tumour-derived cytokines repress drug clearance in the liver and
alter metabolic pathways?
details here
- Molecular analysis of nuclear receptors PXR, RXR and HNF4
details here
- Role of PXR in protecting cells against radiation damage in radiotherapy
details here